Advancing drug development in myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Myelodysplastic Syndromes (MDS)
Urge your Members of Congress to Reverse the 57% Cut to the Congressionally Directed Medical Research Program
Original Publication Date
Article Source
Take Action
Federal budget negotiations are already under way. April 15 marks the 30-Day anniversary of the enactment of the 57% cut to CDMRP including the elimination of all funding to Bone Marrow Failure Research. Every medical research program at CDMRP directly impacts the health and…
2025 San Francisco - Bay Area Patient and Family Conference
Recorded Sessions:
Secondary AML - Webinar 2025
Topic(s)
Acute Myeloid Leukemia (AML)
In this webinar, Drs. Fadi Haddad and Jayastu Senapati discuss the diagnosis secondary AML from MDS, treatment options available to patients and symptom management.
AAMDSIF Supports the Accelerating Kids' Access to Care Act
Original Publication Date
Article Source
Coalition Action
AAMDSIF Supports the Accelerating Kids' Access to Care Act. On March 26, 2025, AAMDSIF joined with 212 additional patient advocacy and medical center organizations in urging members of the US Congress to pass the Accelerating Kids’ Access to Care Act. Passage of this bill will…
How Our Lungs Back Up the Bone Marrow to Make Our Blood
Original Publication Date
Article Source
External Web Content
A study of human lung samples reveals a potent new source of hematopoietic stem cells, which make red blood cells, platelets and immune cells. By Levi Gadye Red blood cells carry oxygen from the lungs to every other organ, and blood-forming stem cells must make about 200 billion…
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Original Publication Date
Article Source
External Web Content
Abstract Outcomes are poor in patients with higher-risk myelodysplastic syndromes (HR MDS) and frontline treatment options are limited. This phase 1b study investigated safety and efficacy of venetoclax, a selective B-cell lymphoma 2 inhibitor, at the recommended phase 2 dose…
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival
Original Publication Date
Article Source
External Web Content
Section snippets Background Myelodysplastic neoplasms (MDS) are a heterogenous group of hematopoietic stem cell malignancies characterized by ineffective hematopoiesis and tendency to progress to acute myeloid leukemia (AML).1 Patients (pts) are risk stratified to tailor…
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
Original Publication Date
Article Source
External Web Content
Dear Editor, Secondary acute myeloid leukemia (sAML), a subset of AML, may arise from antecedent hematologic disorders (antecedent myelodysplastic syndrome or chronic myelomonocytic leukemia [A-MDS/CMML]) or complication of prior cytotoxic chemotherapy or radiation therapy…
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Original Publication Date
Article Source
External Web Content
Abstract Context.—: Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.—: To propose a standardized approach to MDS evaluation in bone marrow specimens by (1)…